Transition Therapeutics Names Carl Damiani COO - Quick Facts

(RTTNews) - Transition Therapeutics Inc. (TTHI, TTH.TO) announced that it has appointed Carl Damiani as its Chief Operating Officer. Damiani has held the roles of Vice-President of Business Development and Director of Business Development, since joining Transition in 2003.

"This appointment reflects Mr. Damiani's broader leadership role in overseeing Transition employees and operations in Toronto, San Francisco and Ireland, as well as advancing our late stage neuropsychiatric drug candidate, ELND005, for AD patients, the phase 2 diabetes drug candidate TT-401 partnered with Lilly, and growing our pipeline with assets acquired from pharma partners", said Tony Cruz, Chairman and Chief Executive Officer.